Page 134 - Malaysian Journal of Health Promotion, Vol 4 (Supplementary 1) 2022

Malaysian Journal of Health Promotion, Vol 4 (Supplementary 1) 2022
rd
14 MOH-AMM Scientific Meeting 2022 in conjunction with 23 NIH Scientific Conference Abstract Book
th
treatment uptake is to plan future strategies in line with the needs of patients. Tailoring LTBI
treatment programs to the needs of our patients will ensure TB elimination can be achieved.

ID 172 HELP! I CAN’T STOP MOVING MY JAW A CASE REPORT ON DRUG-INDUCED
OROMANDIBULAR DYSTONIA

Maisarah Zainuddin, Siti Nur Nabihah Zainul Abidin, Aezy Noorazah Omar
Department of Oral & Maxillofacial Hospital Kajang, Jalan Semenyih, Kajang, Selangor

INTRODUCTION: Oromandibular dystonia clinically manifests as involuntary and forceful
muscle contractions, characteristic rhythmic movements and abnormal posture. These
defaced features affect patient’s quality of life immensely by interfering speech, swallowing
and social interaction which warrants immediate management to identify its aetiology.
CASE REPORT: A 34-year-old lady with underlying Multidrug-Resistant Pulmonary
Tuberculosis (MDR PTB) presented to us with temporomandibular joint (TMJ) pain in
September 2021. Upon history taking, she complained of involuntary jaw movement at night.
However, there was no dystonia noted during clinical examination at that point of time.
Hence, case was managed as per TMJ pain. Unfortunately, she presented to us with apparent
uncontrolled lower jaw movement three months later. Urgent computed tomography (CT) of
brain revealed no focal pathology. Case was co-managed with medical colleague and
benzodiazepine was started by neuromedical team. Immediate resolution was observed.
Further magnetic resonance imaging (MRI) confirmed no pathological changes. By exclusion,
a diagnosis of drug-induced oromandibular dystonia was made due to ongoing medication for
management of MDR PTB.
CONCLUSION: OMD patients may be referred to OMFS clinic. Thus, we should be aware of
the symptoms and its possible causes. Prompt management should be done for patient’s best
interest.

ID 173 ASPERGILLUS FUMIGATUS EXPOSURE IN PATIENTS WITH CHRONIC ILLNESSES IN
MALAYSIAN POPULATION

Noormalin Adullah, Hemahwathy Chanthira Kumar, Nurul Syafiela Zainuddin, Nurul Syafiqah Abdul Khalid, Nur
Farhanah Khalil & Amjad Mohd Rozi
Allergy Unit, Allergy & Immunology Research Centre, Institute for Medical Research, National Institutes of Health,
Ministry of Health Malaysia, Shah Alam, Selangor, Malaysia

INTRODUCTION: Aspergillus fumigatus (AF) is a ubiquitous fungus which produces airborne
conidia (asexual spores). Exposure to AF could cause a spectrum of allergic disease such as
allergic rhinosinusitis, allergic asthma and allergic bronchopulmonary aspergillosis (ABPA).
METHODS: A retrospective analysis of 1,008 patients with either proven or probable AF
exposure among Malaysian patients were selected from diagnostic record data from year
2019 – 2021. Patient demographics such as age, sex, race and underlying disease were
included. Serum was measured for total Immunoglobulin E (IgE) and specific IgE to AF.
RESULTS: About 29.7% (n=299) of the 1008 patients screened were positive to AF. The
positive AF were seen highest in the Malays (60.9%), 16.7% in Indians,13.4% in Chinese and
9.0% in others. The distribution among male and female patients were 47.2% and 52.8%
respectively. Highest positive AF cases were recorded at Kuala Lumpur, followed by Sarawak,
Johor and Selangor. Majority of patients with AF presented with bronchial asthma (45.8%),

108